Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 1,430 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: opiates Clear all

Conditions: Opioid Use
Interventions: Buprenorphine/Naloxone, Treatment as usual; Drug · Other
Lead sponsor: Friends Research Institute, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Opiate Addiction, Pregnancy
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Drug Interactions, Drug Kinetics
Interventions: Alprazolam, Oxycodone, Placebo; Drug
Lead sponsor: Shanna Babalonis, PhD; Other
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Crohn's Disease
Interventions: Naltrexone, Placebo, sugar pill; Drug · Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 6 Years to 17 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Abuse Potential
Interventions: Pregabalin 300mg, pregabalin 450 mg, Pregabalin 300 mg with oxycodone 20 mg, pregabalin 450 mg with oxycodone 20 mg, oxycodone 20 mg, Placebo; Drug
Lead sponsor: Viatris Specialty LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Marlton, New Jersey

Conditions: Healthy, Attention Deficit Hyperactivity Disorder
Interventions: Methylphenidate, Naltrexone, Placebo; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 35 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Migraine With and Without Aura
Interventions: Naltrexone and Acetaminophen Combination, Sumatriptan 100 mg, Placebo; Drug
Lead sponsor: Allodynic Therapeutics, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: North Miami, Florida

Conditions: Cocaine Dependence, Opiate Dependence
Interventions: Atomoxetine, low dose, Atomoxetine, high dose, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Post Operative Pain Control
Interventions: Gabapentin, Acetaminophen, Celecoxib, Dexamethasone, Oxycodone; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Opioid Abuse (Disorder), Opioid Analgesia, Opioid Analgesic Adverse Reaction, Opioid Consumption
Interventions: Naproxen, Acetaminophen, oxycodone, Gabapentin; Drug
Lead sponsor: AdventHealth; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Hypercapnia, Ventilatory Depression
Interventions: Placebo and Oxycodone, Paroxetine and Oxycodone, Escitalopram and Oxycodone; Drug
Lead sponsor: Food and Drug Administration (FDA); Federal
Eligibility: 18 Years to 50 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Opioid Use Disorder
Interventions: Buprenorphine; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cocaine Use Disorder, Opioid Use Disorder, Stimulant Use Disorder
Interventions: n-acetylcysteine, Hydromorphone, Placebo n-acetylcystine, Placebo hydromorphone; Drug
Lead sponsor: William Stoops; Other
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Lexington, Kentucky

Conditions: Cystectomy
Interventions: epidural bupivacaine 0.05%, Liposomal bupivacaine, bupivacaine 0.125%, bupivacaine 0.5%, /hydromorphone 0.05mg/ml, injectable saline; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Elective Cesarean Section, Pain Management
Interventions: 50 mcg Duramorph+ EXPAREL + multi-modal pain regimen, 150 mcg Duramorph + multi-modal pain regimen, Exparel TAP + multi-modal pain regimen; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 18
States / cities: Stanford, California • Gainesville, Florida • Jacksonville, Florida + 13 more

Conditions: Rib Fractures
Interventions: ON-Q bupivicaine administration, IV opioid administration; Device · Drug
Lead sponsor: Cooper Norcross Health; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Tonsillectomy, Pharyngoplasty, Suzetrigine, Opioid, Postoperative Pain, Acute Pain
Interventions: Suzetrigine, Acetaminophen, oxycodone; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Opioid Use Disorder, Opioid Dependence, Chronic Pain
Interventions: Buprenorphine/Naloxone; Drug
Lead sponsor: Theresa Jacob, PhD, MPH; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Procedural Pain, Buprenorphine, Adjuvants, Anesthesia, Dilation and Evacuation, Analgesics
Interventions: Buprenorphine 0.15 MG, Lidocaine 1% Injectable Solution; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Female only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Diego, California

Conditions: Chronic Pain
Interventions: 6 week aerobic exercise intervention, Placebo, Morphine, naloxone; Behavioral · Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Chicago, Illinois • Nashville, Tennessee

Conditions: Drug Dependence
Interventions: Gabapentin, Buprenorphine, Clonidine, Naltrexone (oral), Naltrexone (depot), Placebo; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 65 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Self-Injurious Behavior, Mental Retardation
Interventions: Naltrexone hydrochloride, Transcutaneous sensory nerve stimulation; Drug · Procedure
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 4 Years to 25 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Morganton, North Carolina

Conditions: Kleptomania
Interventions: Naltrexone, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 21 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Baseline Epidemiologic Assessment
Interventions: MorphaBond ER, Comparator Drug; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: Not listed
Enrollment: 17,566 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Basking Ridge, New Jersey

Search by objective public record fields.

Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment

Impact of Pregnancy on Buprenorphine Pharmacokinetics and Pharmacodynamics

Opioid Drug Interaction Study

The Efficacy of Low Dose Naltrexone Therapy in Children With Crohn's Disease

Study Evaluating Abuse Potential of Lyrica® in Healthy Non-Drug Dependent Recreational Opioid Users

Control of Cognition (Naltrexone, Methylphenidate, and ADHD Study (NMAS))

Low-Dose Naltrexone and Acetaminophen Combination and Sumatriptan in the Acute Treatment of Migraine With Nausea

A Drug Treatment for Cocaine Users Who Are Also on Methadone Maintenance Treatment

Effect of a Multimodal Pain Regimen on Pain Control, Patient Satisfaction and Narcotic Use in Orthopaedic Trauma Patients

Reducing Opioid Use After Upper Extremity Surgery: Testing Lower Prescriptions and Pill Quantity

Effect of Selective Serotonin Reuptake Inhibitors (SSRIs) and an Opioid on Ventilation

Oral Buprenorphine as a Novel Low-dose Induction Strategy for Opioid Use Disorder

Behavioral Effects of Drugs (Inpatient): 43 (Opioids, Cocaine, n-Acetylcysteine)

Thoracic Epidural Analgesia Versus Rectus Sheath Block Versus Surgeon Infiltration With Liposomal Bupivacaine or Standard Bupivacaine for Post-Operative Pain Control After Cystectomy

Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section

Pain Relief for Ventilated Patients With Multiple Rib Fractures Using the ON-Q Pain Relief System

Suzetrigine in Tonsillectomy for Opioid-sparing Pain Management

Buprenorphine Treatment: A Safe Alternative for Opioid Dependent Pain Patients

Addition of Buprenorphine to Paracervical Block for Pain Control During Osmotic Dilator Insertion

Reduced Opioid Analgesic Requirements Via Improved Endogenous Opioid Function

Improving Treatment Outcomes for Prescription Opioid Dependence

Self-Injury: Diagnosis and Treatment

Double-Blind Naltrexone in Kleptomania

Baseline Epidemiologic Assessment of Abuse-Deterrence of MorphaBond Extended Release (BEAD-MB)